New York State Teachers Retirement System Sells 2,890 Shares of Sarepta Therapeutics, Inc. $SRPT

New York State Teachers Retirement System decreased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.6% in the second quarter, Holdings Channel reports. The firm owned 76,471 shares of the biotechnology company’s stock after selling 2,890 shares during the quarter. New York State Teachers Retirement System’s holdings in Sarepta Therapeutics were worth $1,308,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ancora Advisors LLC lifted its stake in Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Banque Transatlantique SA bought a new position in shares of Sarepta Therapeutics in the first quarter valued at approximately $44,000. Pandora Wealth Inc. bought a new position in shares of Sarepta Therapeutics in the first quarter valued at approximately $45,000. Brooklyn Investment Group raised its stake in shares of Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 590 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Sarepta Therapeutics by 542.3% in the second quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 2,771 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft lifted their price objective on Sarepta Therapeutics to $12.00 and gave the company a “sell” rating in a research report on Friday, August 15th. UBS Group reiterated a “neutral” rating on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Jefferies Financial Group cut their price objective on Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Thursday, July 24th. JPMorgan Chase & Co. upgraded Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 price objective for the company in a research report on Tuesday, July 29th. Finally, William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. Eight research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and seven have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $34.42.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $22.47 on Thursday. The firm has a fifty day moving average of $19.85 and a two-hundred day moving average of $28.70. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -25.83 and a beta of 0.51. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $138.81. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating the consensus estimate of $0.89 by $1.13. The company had revenue of $611.09 million during the quarter, compared to analysts’ expectations of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business’s revenue for the quarter was up 68.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.07 EPS. As a group, equities research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.